Pure Global
NCT02809573

Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients

An Open-label, Multi-center, Phase Ib Clinical Trial of Chidamide Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphoma Patients
Chipscreen Biosciences, Ltd.·Phase 1·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Peripheral T-cell Lymphoma
Drug/Device/Intervention
Chidamide
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Chipscreen Biosciences, Ltd.
Location
Beijing, China
Timeline & enrollment
Phase
Phase 1
Start date
Aug 11, 2016
End date
Jan 08, 2019
Enrollment
30 participants
Primary outcome

dose-limiting toxicity (DLT)

Summary

The purpose of this dose-escalation study is to assess the safety and tolerability of
 treatment with Chidamide in a range of doses combined with CHOP in fixed dose in patients
 with newly diagnosed peripheral T-cell lymphoma.

ICD-10 classifications
Peripheral T-cell lymphoma, not elsewhere classifiedCutaneous T-cell lymphoma, unspecifiedMature T/NK-cell lymphomasAngioimmunoblastic T-cell lymphomaOther mature T/NK-cell lymphomas
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT02809573
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT02809573 through Pure Global AI's free database. This Phase 1 trial is sponsored by Chipscreen Biosciences, Ltd. and is currently Completed. The study focuses on Peripheral T-cell Lymphoma. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.